JP2023520233A - 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法 - Google Patents

間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法 Download PDF

Info

Publication number
JP2023520233A
JP2023520233A JP2022560101A JP2022560101A JP2023520233A JP 2023520233 A JP2023520233 A JP 2023520233A JP 2022560101 A JP2022560101 A JP 2022560101A JP 2022560101 A JP2022560101 A JP 2022560101A JP 2023520233 A JP2023520233 A JP 2023520233A
Authority
JP
Japan
Prior art keywords
cells
subject
mlpscs
treatment
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520233A5 (https=
Inventor
シルヴィウ・イテスク
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901052A external-priority patent/AU2020901052A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2023520233A publication Critical patent/JP2023520233A/ja
Publication of JP2023520233A5 publication Critical patent/JP2023520233A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022560101A 2020-04-03 2021-04-01 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法 Pending JP2023520233A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
AU2020901052 2020-04-03
AU2020901052A AU2020901052A0 (en) 2020-04-03 Method for treating hyperinflammation which comprise administering mesenchymal lineage precursor or stem cells
AU2020901124 2020-04-08
AU2020901124A AU2020901124A0 (en) 2020-04-08 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312A AU2020902312A0 (en) 2020-07-06 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312 2020-07-06
AU2020902425A AU2020902425A0 (en) 2020-07-14 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902425 2020-07-14
AU2020903041 2020-08-25
AU2020903041A AU2020903041A0 (en) 2020-08-25 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903694 2020-10-12
AU2020903694A AU2020903694A0 (en) 2020-10-12 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020904312 2020-11-23
AU2020904312A AU2020904312A0 (en) 2020-11-23 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
PCT/EP2021/058683 WO2021198454A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Publications (2)

Publication Number Publication Date
JP2023520233A true JP2023520233A (ja) 2023-05-16
JP2023520233A5 JP2023520233A5 (https=) 2024-04-12

Family

ID=77927537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560101A Pending JP2023520233A (ja) 2020-04-03 2021-04-01 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法

Country Status (9)

Country Link
US (1) US20230165904A1 (https=)
EP (1) EP4125957A1 (https=)
JP (1) JP2023520233A (https=)
KR (1) KR20220164741A (https=)
CN (1) CN115361959A (https=)
AU (1) AU2021245369A1 (https=)
BR (1) BR112022020042A2 (https=)
CA (1) CA3173216A1 (https=)
WO (1) WO2021198454A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
US12067745B2 (en) 2022-09-27 2024-08-20 Kla Corporation Image pre-processing for overlay metrology using decomposition techniques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
JP6173157B2 (ja) * 2013-10-02 2017-08-02 日本製薬株式会社 Ｉｌ−１７産生抑制組成物
CN110101873A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用il-10转基因的干细胞治疗ards的方法
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"NCT04456439 ver. 1, Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC)", CLINICALTRIALS.GOV [ONLINE], JPN6026001169, 30 June 2020 (2020-06-30), ISSN: 0005774679 *
AGING AND DISEASE, vol. 11, JPN6025017820, 9 March 2020 (2020-03-09), pages 216 - 228, ISSN: 0005774676 *
ENGINEERING, vol. 6, JPN6025017821, 28 February 2020 (2020-02-28), pages 1153 - 1161, ISSN: 0005774677 *
LIANG, BING ET AL.: "Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal", CHINAXIV, JPN6026001168, 27 February 2020 (2020-02-27), ISSN: 0005774678 *

Also Published As

Publication number Publication date
CA3173216A1 (en) 2021-10-07
KR20220164741A (ko) 2022-12-13
BR112022020042A2 (pt) 2022-11-22
CN115361959A (zh) 2022-11-18
AU2021245369A1 (en) 2022-11-03
US20230165904A1 (en) 2023-06-01
WO2021198454A1 (en) 2021-10-07
EP4125957A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP2023520233A (ja) 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法
US20230097931A1 (en) Method for treating chronic graft versus host disease
JP2023517641A (ja) 炎症性腸疾患を治療するための方法ｉｉ
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
CN117337184A (zh) 使用间充质谱系前体细胞或干细胞治疗急性呼吸窘迫综合征(ards)的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417